Benefits of Alcoholic Hangover Medicine
Launched by THE GUT MICROBIOME CENTER (CENTAR ZA CRIJEVNI MIKROBIOM) · Nov 8, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a dietary supplement called Myrkl, which is marketed to help prevent hangover symptoms after drinking alcohol. The researchers want to see how Myrkl affects the gut bacteria, which play an important role in our overall health. To do this, they will ask participants to provide stool samples and complete questionnaires before, during, and after using the supplement. They will also conduct cognitive tests and collect blood samples to gather more information.
To be eligible for the trial, participants must be female fraternal twins who live and work together. It's important to note that those who have taken probiotics or antibiotics in the 30 days before the study, or who are unable to drink alcohol, will not be able to participate. The trial is not yet recruiting participants, but once it starts, those who take part can expect to contribute valuable information that may help improve our understanding of how Myrkl affects gut health and hangover symptoms.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • • fraternal twins who live and work together
- Exclusion Criteria:
- • consumption of other probiotics, antibiotics 30 days before the research
- • Inability to drink alcohol
About The Gut Microbiome Center (Centar Za Crijevni Mikrobiom)
The Gut Microbiome Center (Centar za crijevni mikrobiom) is a leading research institution dedicated to advancing the understanding of the gut microbiome's role in human health and disease. Committed to innovative clinical trials and translational research, the center focuses on exploring the complex interactions between gut microbiota and various physiological processes. By fostering collaboration among experts in microbiology, immunology, and clinical medicine, the Gut Microbiome Center aims to develop novel therapeutic strategies and personalized approaches that harness the potential of the microbiome to improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zagreb, , Croatia
Patients applied
Trial Officials
Andrija Karačić, dr.med
Study Director
Centar za crijevni mikrobiom
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported